Phosphodiesterase Enzyme Inhibitors Market Analysis With Global Business Opportunities

Phosphodiesterase Enzyme (PDE) Inhibitors
Market Size, Share, Trend, Outlook, Future
Growth Analysis And Synthesis 2018 - 2026
Phosphodiesterase are a diverse family of enzymes (11 isoenzymes) that play a key role in regulating
intracellular levels of secondary messengers - cyclic adenosine monophosphate (cAMP) and cyclic
guanosine monophosphate. These enzymes identified to be pharmacologically active in the 1950s,
hydrolyses cyclic nucleotides to treat various diseases such as cardiovascular, respiratory and erectile
dysfunction. Distinct distribution of all the types of isoenzymes has provided possibilities for selective
target therapies.
The global phosphodiesterase enzyme inhibitors market can be better analyzed by classifying it into two
classes as selective phosphodiesterase enzyme inhibitors and non-selective phosphodiesterase enzyme
inhibitors. Theophylline and papaverineare the two most commonly used non-selective phosphodiesterase
enzyme inhibitors for treating a range of diseases (bronchodilation, cardiac disorder, etc.). Advent of
selective phosphodiesterase enzyme inhibitors has made a great impact in the medical treatment sector.
Increasing understanding of the individual PDE isoforms has and will result in the emergence of better
therapeutic drugs. Viagra (Sildenafil) is the best example to substantiate the success and impact of PDE
Free Request Sample of Report:
Increasing product developments to further improvise the phosphodiesterase enzyme inhibitors market
The global phosphodiesterase enzyme inhibitors market has recently gained traction on account of the
blockbuster PDE 5 inhibitor brands, Viagra and Cialis. This has also encouraged pharmaceutical
companies to research on other PDE inhibitor class. In addition, research on extended use of approved
PDE inhibitors is anticipated to benefit the drug in long term and contribute to the increasing revenues
of PDE inhibitors market.
Researchers from the John Hopkin University reviewed the trials of PDE-5 inhibitors in pediatric
patients with pulmonary hypertension. The researchers concluded that PDE-5 inhibitors can be
safely prescribed to infants, neonates and children with primary and secondary pulmonary
hypertension (2017).
Besides, PDE-5 inhibitor sildenafil accidently developed for treating angina, was also found to be
effective in erectile dysfunction and now is observed to benefit heart attack patients. Researchers
at Karolinska Institutet, Sweden reported in March 2017 that PDE-5 inhibitors prescribed for
erectile dysfunction can lower the risk of death of hospitalization for heart failure in men who
have had one heart attack in their lifetime.
Pfizer, Inc. received FDA approval for its PDE-4 inhibitor Crisaborole (Eucris) in December 2016
for the treatment of mild to moderate atopic dermatitis. Eucrisa the first non-steroidal topical
monotherapy for skin disorder.
Report includes chapters which deeply display the following deliverable about industry :
• Phosphodiesterase Enzyme Inhibitors Market Research Objective and Assumption
• Phosphodiesterase Enzyme Inhibitors Market Purview - Report Description, Executive
Summary, and Coherent Opportunity Map (COM)
• Phosphodiesterase Enzyme Inhibitors Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Phosphodiesterase Enzyme Inhibitors Market, By Regions
• Phosphodiesterase Enzyme Inhibitors Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Phosphodiesterase Enzyme Inhibitors Market Manufacturers Profiles/Analysis including
Company Basic Information, Manufacturing Base and Its Competitors.
• Phosphodiesterase Enzyme Inhibitors Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Phosphodiesterase Enzyme Inhibitors Market Forecast including Production, Consumption,
Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Key Players
Some of the key players operating in the global phosphodiesterase enzyme inhibitors market include
Pfizer, Inc., AstraZeneca plc, Bayer AG, Eli Lilly & Company, Celgene Corporation, Mist Pharmaceuticals.
Market Taxonomy
The global phosphodiesterase enzyme inhibitors market is therefore analyzed based on the drug class and
application as follows:
• Drug Class
- Selective PDE inhibitors
- Non-selective PDE inhibitors
• Application
Cardiovascular Disease
Respiratory Disease
Erectile Dysfunction
Pulmonary Hypertension
Benign Prostate Hyperplasia
Browse In-Depth Analysis Research Report @
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Phosphodiesterase are a diverse family of enzymes (11 isoenzymes) that play a key role in regulating intracellular levels of secondary messengers.